Fuyuan Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 186 million yuan, a decrease of 30.49% compared with the same period last year. The company's total operating revenue was 1.71 billion yuan, up 4.66% year-on-year; net cash inflow from operating activities was 257 million yuan, up 17.80% year-on-year. The company's latest gross margin was 60.18%, a decrease of 6.31 percentage points from the same period last year; the latest return on equity was 4.99%, a decrease of 2.50 percentage points from the same period last year. Diluted earnings per share were 0.40 yuan, down 28.57% year-on-year.
Beijing Winsunny Pharmaceutical CO.LTDNet profit down 30.49% year-on-year, with lower gross margin and ROE.
